

Hemophilia A Treatment Market - 2022-2031

<https://marketpublishers.com/r/H2497AC49C1EEN.html>

Date: November 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: H2497AC49C1EEN

Abstracts

The Hemophilia A Treatment Market was valued at US\$ 9.1 billion in 2022 and is anticipated to reach US\$ 13.3 billion by 2031, at a CAGR of 0.05 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hemophilia A Treatment Market.

This report delivers a comprehensive overview of the Hemophilia A Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemophilia A Treatment Market. The Hemophilia A Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Hemophilia A Treatment Market Scope:

By Treatment Type

Factor Replacement Therapy

Non-Factor Replacement Therapies

Gene Therapy

By Route of Administration

Intravenous

Oral

Nasal

By Severity Type

Mild Hemophilia A

Moderate Hemophilia A

Severe Hemophilia A

By Distribution Channel

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Takeda Pharmaceutical Company Limited

SANOFI CORPORATION

Genentech USA, Inc.

Novo Nordisk

Pfizer Inc.

CSL Behring LLC.

Grifols

Sagent Pharmaceuticals

Octapharma USA Inc.

UBI Pharma Inc.

Major Highlights

This report delivers a comprehensive overview of the Hemophilia A Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemophilia A Treatment Market. The Hemophilia A Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Treatment Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Severity Type
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. The Rising Prevalence of Hemophilia A
 - 4.1.1.2. The Advancements in Gene Therapies
 - 4.1.2. Restraints
 - 4.1.2.1. The High Cost Associated with the Hemophilia A Treatment A
 - 4.1.3. Opportunity
 - 4.1.3.1. Increasing Demand for Personalized Medicine
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19

- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY TREATMENT TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 7.1.2. Market Attractiveness Index, By Treatment Type
- 7.2. Factor Replacement Therapy*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 7.2.2.1. Recombinant Factor VIII
 - 7.2.2.2. Plasma-derived Factor VIII
- 7.3. Non-Factor Replacement Therapies
 - 7.3.1. Emicizumab
 - 7.3.2. Desmopressin
 - 7.3.3. Aminocaproic Acid
- 7.4. Gene Therapy

8. BY ROUTE OF ADMINISTRATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Intravenous *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Oral
- 8.4. Nasal

9. BY SEVERITY TYPE

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

9.1.2. Market Attractiveness Index, By Severity Type

9.2. Mild Hemophilia A*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Moderate Hemophilia A

9.4. Severe Hemophilia A

10. BY DISTRIBUTION CHANNEL

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.1.2. Market Attractiveness Index, By Distribution Channel

10.2. Hospitals Pharmacies*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Retail Pharmacies

10.4. Online Pharmacies

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. U.K.

11.3.7.3. France

11.3.7.4. Spain

11.3.7.5. Italy

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia-Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. Australia

11.5.7.5. Rest of Asia-Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Severity Type

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario

12.2. Market Positioning/Share Analysis

12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Takeda Pharmaceutical Company Limited*

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Financial Overview

13.1.4. Key Developments

13.2. SANOFI CORPORATION

13.3. Genentech USA, Inc.

13.4. Novo Nordisk

13.5. Pfizer Inc.

13.6. CSL Behring LLC.

13.7. Grifols

13.8. Sagent Pharmaceuticals

13.9. Octapharma USA Inc.

13.10. UBI Pharma Inc. (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Hemophilia A Treatment Market - 2022-2031

Product link: <https://marketpublishers.com/r/H2497AC49C1EEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H2497AC49C1EEN.html>